Venetoclax Active in Heavily Treated Multiple Myeloma

Published: Wednesday, Dec 21, 2016

Shaji Kumar, MD

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma, according to results of a phase I clinical trial presented at the 2016 ASH Annual Meeting.¹

References

Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Presented at: 58th ASH Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA. Abstract 488.
Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210-212.
Punnoose EA, Leverson JD, Peale F. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132-1144.

... to read the full story

To Read the Full Story

View Other News on Multiple Myeloma

View Conference Coverage

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

2019 State of the Science Summit on Hematologic Malignancies in Seattle

15th International Conference on Malignant Lymphoma

2019 European Hematology Association Congress

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies	Jul 30, 2019	1.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?	Jul 31, 2019	1.5